Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer

PURPOSE: With the recent approval of the KRAS G12C inhibitor sotorasib for patients with advanced KRAS G12C-mutant non–small cell lung cancer (NSCLC), there is a new need to identify factors associated with activity and toxicity among patients treated in routine practice. MATERIALS AND METHODS: We c...

Descripción completa

Detalles Bibliográficos
Autores principales: Thummalapalli, Rohit, Bernstein, Ezra, Herzberg, Benjamin, Li, Bob T., Iqbal, Afsheen, Preeshagul, Isabel, Santini, Fernando C., Eng, Juliana, Ladanyi, Marc, Yang, Soo-Ryum, Shen, Ronglai, Lito, Piro, Riely, Gregory J., Sabari, Joshua K., Arbour, Kathryn C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581626/
https://www.ncbi.nlm.nih.gov/pubmed/37384866
http://dx.doi.org/10.1200/PO.23.00030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581626/
https://www.ncbi.nlm.nih.gov/pubmed/37384866
http://dx.doi.org/10.1200/PO.23.00030

Ejemplares similares